CellaVision AB
The answer first
Does CellaVision beat the market?
Yes, CellaVision has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 84% of Nordic stocks
- Quality99
- Value13
- Trend91
No. 21 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash CellaVision keeps must grow about 12% a year for 10 years.
Max for seven days
Follow CellaVision with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about CellaVision
Your first answer is free, no account needed.
Do you own CellaVision, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with CellaVision and a few more. Free, no card.
Super Stock+44.6%In short
- CellaVision has risen 35.4% over the past year, including dividends.
- Overall, CellaVision ranks better than 84% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 67.3%. The price is 56.0% below its peak now.
What do analysts think of CellaVision?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 84% of Nordic stocks.
No. 21 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 5 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.06
- Asset turnoverSales divided by everything the company owns0.64
- Return on equityProfit divided by equity+14.8%
- Cash conversionOperating cash flow divided by profit1.53
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 127 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity5.1
- P/SPrice divided by sales6.3
- P/EPrice divided by earnings34.7
- P/CFPrice divided by operating cash flow22.7
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 23 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+24.4%
- 6 months+63.6%
- 9 months+36.1%
- 12 months+35.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own CellaVision
15 funds we follow own CellaVision. The share is how much of the fund the stock makes up.
- Norway1
- Sweden14
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo4.3%
- Case All StarSweden · Case2.9%
- TIN Småbolag ASweden · TIN2.4%
- PLUS Mikrobolag Sverige IndexSweden · PLUS2.0%
- PLUS Hälsovård Sverige IndexSweden · PLUS0.9%
- AMF Aktiefond SmåbolagSweden · AMF0.9%
- Länsförsäkringar Småbolag Sverige ASweden · Länsförsäkringar0.5%
- Kvartil Nordiska Småbolag+ Faktor ASweden · Kvartil0.1%
Show all 15
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.1%
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.1%
- Skandia Sverige ExponeringSweden · Skandia0.0%
- Öhman Etisk Index Sverige ASweden · Öhman0.0%
- KLP AksjeNorden IndeksNorway · KLP0.0%
- Skandia Världen SverigeSweden · Skandia0.0%
- SPP Aktiefond Sverige ASweden · SPP0.0%
From the funds' latest known holdings.
About CellaVision
CellaVision AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 250 employees.
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials.


See the full analysis of CellaVision.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card